REPLIGEN CORP (RGEN): Unregistered Sales of Equity Securities
REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Exhibit 99.1 October 29, 2026 Repligen Corporation 41 Seyon Street, Bldg. 1, Suite 100 Waltham, MA 02453 Attention: Chief Financial Officer Re: Exchange and/or Subscription for Repligen Corporation 0.25% Convertible Senior Notes due 2031 Ladies and Gentlemen: Repligen Corporation
- Instrument
- 0.25% Convertible Senior Notes due 2031
- Coupon
- 0.25%
- Maturity
- 2031
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The offering introduces potential dilution and additional debt, likely pressuring the share price in the short term. However, the cash proceeds could fund growth initiatives.
Market read
Primary corporate action for a listed biotech; relevant for investors in RGEN and those monitoring convertible note markets.
What to watch
The terms allow conversion into cash or shares, giving investors flexibility that may mitigate dilution risk.
Background
Repligen Corp (RGEN) is a biopharmaceutical company focused on protein purification technologies. The 8‑K filing details a new convertible note offering and unregistered equity sales under Regulation D exemptions.
Ticker impact
Repligen Corp filed an 8‑K announcing a new series of 0.25% convertible senior notes due 2031 and unregistered sales of equity securities.
downward pressure as market prices in potential dilution and added leverage
Primary disclosure of a capital raise without disclosed amount; typical market reaction to dilution is negative.
Market effects
May signal increased financing activity in the biotech/biopharma sector, potentially prompting peers to consider similar funding structures.
Limited to U.S. markets where Repligen trades; no broader regional effect anticipated.
Low global relevance beyond investors tracking convertible note issuances.
Counterpoint
If the capital raised is used for high‑impact R&D, the long‑term upside could outweigh short‑term dilution concerns.
Key entities
- companyRepligen Corp
Issuer of the new convertible senior notes.
- trusteeU.S. Bank Trust Company, National Association
Trustee for the new notes.

